Pamiparib
- Generic Name
- Pamiparib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C16H15FN4O
- CAS Number
- 1446261-44-4
- Unique Ingredient Identifier
- 8375F9S90C
- Background
Pamiparib is under investigation in clinical trial NCT03933761 (Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy).
- Indication
用于既往经过二线及以上化疗的伴有胚系BRCA(gBRCA)突变的复发性晚期卵巢癌、输卵管癌或原发性腹膜癌患者的治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT05038839
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 60
- Registration Number
- NCT04985721
- Locations
- 🇦🇺
Austin Hospital, Heidelberg, Victoria, Australia
🇦🇺St Vincent's Hospital, Fitzroy, Victoria, Australia
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Pamiparib and Low Dose Temozolomide In Patients With Platinum Sensitive Biliary Tract Cancer
- Conditions
- Interventions
Study of Pamiparib in Newly Diagnosed and rGBM
- Conditions
- Interventions
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Nader Sanai
- Target Recruit Count
- 30
- Registration Number
- NCT04614909
- Locations
- 🇺🇸
St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer
- Conditions
- Clear Cell Papillary Renal NeoplasmHereditary Leiomyomatosis and Renal Cell CarcinomaCollecting Duct CarcinomaMetastatic Unclassified Renal Cell CarcinomaPapillary Renal Cell CarcinomaStage III Renal Cell Cancer American Joint Committee on Cancer (AJCC) v8Unresectable Renal Cell CarcinomaHereditary Papillary Renal Cell CarcinomaMetastatic Renal Cell CarcinomaStage IV Renal Cell Cancer AJCC v8
- Interventions
- First Posted Date
- 2020-10-26
- Last Posted Date
- 2023-05-17
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT04603365
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 300
- Registration Number
- NCT04164199
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang, Jiangxi, China
Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-06-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 25
- Registration Number
- NCT03994211
- Locations
- 🇬🇪
Arensia Exploratory Medicine Llc, Tbilisi, Georgia
🇵🇱Szpital Luxmed, Warszawa, Poland
🇸🇰Summit Clinical Research, Sro, Bratislava, Slovakia
Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy
Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency
- Conditions
- Interventions
- First Posted Date
- 2018-10-19
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 13
- Registration Number
- NCT03712930
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
🇦🇺Liverpool Hospital, Liverpool, New South Wales, Australia
🇺🇸University Cancer and Blood Center, Athens, Georgia, United States
Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-02-09
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 136
- Registration Number
- NCT03427814
- Locations
- 🇺🇸
Scri Florida Cancer Specialist East, West Palm Beach, Florida, United States
🇺🇸Goshen Center For Cancer Care, Goshen, Indiana, United States
🇺🇸Novant Health Hematology Charlotte, Charlotte, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.